A Phase 3 interventional study of Zoledronic Acid and Letrozole in Breast Neoplasms and Osteoporosis, sponsored by Novartis Pharmaceuticals. Completed at 44 sites in 2 countries. Open to female participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2014-03-21.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies testing Zoledronic Acid in Breast Neoplasms — none open to participants now, 2 under way, 1 of them phase 3. Zoledronic Acid · Breast Neoplasms.
Among the 59 studies testing Zoledronic Acid in Breast Neoplasms, this one is the 9th largest by enrollment of the 56 interventional ones that give a count, is one of 5 that started in 2002, is one of 24 in phase 3, and was the 4th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →None of the 59 studies testing Zoledronic Acid in Breast Neoplasms is open now. The open studies under Breast Neoplasms, anywhere →
Zoledronic Acid: first FDA approval 2001 (ZOMETA), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years to 85 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 16 · Phase 3 27 · Phase 4 11
First in 1999; this study’s year is marked. 5 started in 2002.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 602 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 98 across the 56 interventional studies. Of the 52 that completed or were terminated, 21 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 59 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
199 studies in Breast Neoplasms by Novartis: 16 open now, 30 under way, 4 of them phase 3. Of 160 finished, 74 (46%) have results posted.
Among the 199 studies in Breast Neoplasms by Novartis, this one is the 16th largest by enrollment of the 155 interventional ones that give a count, is one of 5 that started in 2002, is one of 45 in phase 3, and was the 6th registered.
Novartis’s Breast Neoplasms studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 59 studies testing Zoledronic Acid in Breast Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 199 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
This protocol is designed to compare the effect on bone of Zoledronic Acid 4 mg every 6 months when given upfront versus delayed start (based on a post-baseline BMD T- Score below -2.0 SD at either the lumbar spine or total hip, or any clinical fracture unrelated to trauma, or an asymptomatic fracture discovered at the month 36 scheduled visit) in stage I-IIIb postmenopausal women with hormone receptor positive breast cancer who will receive Letrozole 2.5 mg daily as an adjuvant therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
status defined by one of the following :
Adequately diagnosed and treated breast cancer defined as:
Hormone receptor positive defined as:
The date of randomization must not be more than the following:
Exclusion criteria:
Additional Exclusion Criteria: (for Spine DXA)
Additional protocol-defined inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in the upfront arm received zoledronate 4 mg i.v. on Day 1 and every 6 months until disease progression (recurrence) or the end of study. Participants also received Letrozole 2.5 daily plus calcium (1000-1200 mg) and vitamin D (400-800 IU) daily.
Drug: Zoledronic Acid · Drug: Letrozole
In lieu of a placebo arm, which was considered unethical for this trial, a delayed start arm was used. Participants who met certain clinical criteria indicating risk of lumbar spine or total hip fracture, or experienced clinical fracture unrelated to trauma or any asymptomatic fracture discovered at the Month 36 scheduled visit, were started on zoledronate 4 mg i.v. and for every 6 months until disease progression (recurrence) or end of study. Participants also received Letrozole 2.5 daily plus calcium (1000-1200 mg) and vitamin D (400-800 IU) daily.
Drug: Zoledronic Acid · Drug: Letrozole
Participants received Zoledronate 4 mg IV 15-minute infusion every 6 months.
Also known as: ZOL446, Zoledronate
Participants received Letrozole 2.5 mg daily.
Also known as: Femara
Percent Change From Baseline in Lumbar Spine (L1-L4) Bone Mineral Density (BMD)
Bone mineral density (BMD) measurements were assessed by dual energy x-ray absorptiometry (DXA). The DXA devices of participating sites were cross-calibrated and the DXA results were compiled and analyzed by a central reader. Percent change = 100\*((BMD at Month 12 - Baseline BMD)/Baseline BMD)). Missing data at month 12 were imputed by using the last observation carried forward (LOCF) method. Post-baseline non-missing data from month 6 were carried forward to month 12. Data prior to month 6 were not carried forward.
Time frame: Baseline, 12 months
Percent Change From Baseline in Lumbar Spine (L1-L4) BMD
Bone mineral density (BMD) measurements were assessed by dual energy x-ray absorptiometry (DXA). The DXA devices of participating sites were cross-calibrated and the DXA results were compiled and analyzed by a central reader. Percent change = 100\*((BMD at Time Frame - Baseline BMD)/Baseline BMD)). Missing data beyond month 12 were not imputed by LOCF.
Time frame: Baseline, 2 years, 3 years, 5 years
Percent Change From Baseline in Total Hip BMD
Bone mineral density (BMD) measurements were assessed by dual energy x-ray absorptiometry (DXA). The DXA devices of participating sites were cross-calibrated and the DXA results were compiled and analyzed by a central reader. Percent change = 100\*((BMD at Time Frame - Baseline BMD)/Baseline BMD)). Missing data at month 12 were imputed by using the LOCF method. Post-baseline non-missing data from month 6 were carried forward to month 12. Data prior to month 6 were not carried forward.
Time frame: Baseline, 12 months, 2 years, 3 years, 5 years
Percent Change From Baseline in Biochemical Markers of Bone Turnover, Serum N-Telopeptide (sNTX) and Bone-specific Alkaline Phosphatase (BSAP)
Blood samples from a subset of participants (231 participants in total) were collected to measure the sNTX and BSAP. Missing data at month 12 were imputed by using the LOCF method. Post-baseline non-missing data from months 6 and 9 were carried forward to month 12. Data prior to month 6 were not carried forward. Missing data beyond month 12 were not imputed by LOCF.
Time frame: Baseline, 12 months, 2 years, 3 years, 5 years
Incidence Rate of All Clinical Fractures
The number of participants who experienced a clinical fracture at month 36 was assessed. Initial x-ray (both AP and lateral views) of the lumbar and thoracic spine were performed at baseline to exclude participants with evidence of fracture. In addition, repeated bone scan and/or x-ray were performed at the Principal Investigator's discretion during the course of the study to confirm evidence of clinical fracture, or at month 36 if there was no evidence of clinical fracture (lumbar and thoracic spine - lateral view). X-ray films were sent to a central reader.
Time frame: 3 years
Time to Disease Recurrence/Relapse
The median time to disease progression was assessed by Kaplan-Meier analysis. The Principal Investigator assessed each participant for disease recurrence at each visit. Further testing was performed at the discretion of the Principal Investigator and as clinically indicated. Disease progression was defined as chest wall and/or regional recurrence confirmed by positive cytology or biopsy, and/or distance recurrence of the 1) skin, subcutaneous tissue, and lymph nodes (other than local or regional), 2) bone marrow, 3) lung, 4) skeleton 5) liver and 6) central nervous system confirmed by positive cytology, biopsy, aspirate or radiology as appropriate.
Time frame: over 5 years
Rate of Change From Baseline in Lumbar Spine (L1-L4) BMD
The rate of change from baseline in BMD was assessed.
Time frame: Baseline, 5 years
Rate of Change From Baseline in Total Hip BMD
The rate of change from baseline in BMD was assessed.
Time frame: Baseline, 5 years
| Milestone | Zoledronic Acid Upfront | Zoledronic Acid Delayed-start |
|---|---|---|
| Started | 301 | 301 |
| Intent-to-treat population | 300 | 300 |
| Completed | 180 | 175 |
| Not completed | 121 | 126 |
| Withdrew: Adverse event | 41 | 46 |
| Withdrew: Abnormal laboratory value(s) | 1 | 1 |
| Withdrew: Abnormal test procedure results | 0 | 1 |
| Withdrew: Lack of efficacy | 16 | 21 |
| Withdrew: Participant condition no longer required | 1 | 0 |
| Withdrew: Protocol violation | 4 | 10 |
| Withdrew: Withdrawal by subject | 34 | 26 |
| Withdrew: Lost to follow-up | 7 | 9 |
| Withdrew: Administrative problems | 10 | 6 |
| Withdrew: Death | 7 | 4 |
| Withdrew: Unknown - reason is missing | 0 | 2 |
Bone mineral density (BMD) measurements were assessed by dual energy x-ray absorptiometry (DXA). The DXA devices of participating sites were cross-calibrated and the DXA results were compiled and analyzed by a central reader. Percent change = 100\*((BMD at Month 12 - Baseline BMD)/Baseline BMD)). Missing data at month 12 were imputed by using the last observation carried forward (LOCF) method. Post-baseline non-missing data from month 6 were carried forward to month 12. Data prior to month 6 were not carried forward.
| Percentage of BMD | Zoledronic Acid Upfront | Zoledronic Acid Delayed-start |
|---|---|---|
| Percent Change From Baseline in Lumbar Spine (L1-L4) Bone Mineral Density (BMD) | 1.955 ± 3.3658 | -2.325 ± 3.9542 |
Bone mineral density (BMD) measurements were assessed by dual energy x-ray absorptiometry (DXA). The DXA devices of participating sites were cross-calibrated and the DXA results were compiled and analyzed by a central reader. Percent change = 100\*((BMD at Time Frame - Baseline BMD)/Baseline BMD)). Missing data beyond month 12 were not imputed by LOCF.
| Percentage of BMD | Zoledronic Acid Upfront | Zoledronic Acid Delayed Start |
|---|---|---|
| 2 years (n=206,202) | 3.137 ± 4.1599 | -2.889 ± 5.0783 |
| 3 years (n=189,190) | 3.853 ± 4.5414 | -2.990 ± 5.7925 |
| 5 years (n=140,132) | 6.192 ± 5.9723 | -2.418 ± 7.4545 |
Bone mineral density (BMD) measurements were assessed by dual energy x-ray absorptiometry (DXA). The DXA devices of participating sites were cross-calibrated and the DXA results were compiled and analyzed by a central reader. Percent change = 100\*((BMD at Time Frame - Baseline BMD)/Baseline BMD)). Missing data at month 12 were imputed by using the LOCF method. Post-baseline non-missing data from month 6 were carried forward to month 12. Data prior to month 6 were not carried forward.
| Percentage of BMD | Zoledronic Acid Upfront | Zoledronic Acid Delayed Start |
|---|---|---|
| 12 months (n=253,256) | 1.256 ± 2.5878 | -1.883 ± 3.3007 |
| 2 years (n=208,200) | 1.413 ± 2.9178 | -3.150 ± 4.0450 |
| 3 years (n=187,189) | 1.676 ± 3.6979 | -3.463 ± 5.2585 |
| 5 years (n=141,132) | 2.571 ± 4.8794 | -4.115 ± 6.1071 |
Blood samples from a subset of participants (231 participants in total) were collected to measure the sNTX and BSAP. Missing data at month 12 were imputed by using the LOCF method. Post-baseline non-missing data from months 6 and 9 were carried forward to month 12. Data prior to month 6 were not carried forward. Missing data beyond month 12 were not imputed by LOCF.
| Percentage of biochemical markers | Zoledronic Acid Upfront | Zoledronic Acid Delayed Start |
|---|---|---|
| sNTX, 12 months (n=87,85) | -20.1 ± 42.1 | 21.7 ± 55.2 |
| sNTX, 2 years | NA ± NA | NA ± NA |
| sNTX, 3 years | NA ± NA | NA ± NA |
| sNTX, 5 years | NA ± NA | NA ± NA |
| BSAP, 12 months (n=88,90) | -7.8 ± 28.2 | 19.0 ± 39.2 |
| BSAP, 2 years (n=63,60) | -12.0 ± 26.3 | 19.9 ± 48.1 |
| BSAP, 3 years (n=59,52) | -12.4 ± 23.2 | 10.6 ± 42.2 |
| BSAP, 5 years (n=95,102) | -6.4 ± 35.4 | 11.9 ± 41.0 |
The number of participants who experienced a clinical fracture at month 36 was assessed. Initial x-ray (both AP and lateral views) of the lumbar and thoracic spine were performed at baseline to exclude participants with evidence of fracture. In addition, repeated bone scan and/or x-ray were performed at the Principal Investigator's discretion during the course of the study to confirm evidence of clinical fracture, or at month 36 if there was no evidence of clinical fracture (lumbar and thoracic spine - lateral view). X-ray films were sent to a central reader.
| Participants | Zoledronic Acid Upfront | Zoledronic Acid Delayed Start |
|---|---|---|
| Incidence Rate of All Clinical Fractures | 18 | 21 |
The median time to disease progression was assessed by Kaplan-Meier analysis. The Principal Investigator assessed each participant for disease recurrence at each visit. Further testing was performed at the discretion of the Principal Investigator and as clinically indicated. Disease progression was defined as chest wall and/or regional recurrence confirmed by positive cytology or biopsy, and/or distance recurrence of the 1) skin, subcutaneous tissue, and lymph nodes (other than local or regional), 2) bone marrow, 3) lung, 4) skeleton 5) liver and 6) central nervous system confirmed by positive cytology, biopsy, aspirate or radiology as appropriate.
| months | Zoledronic Acid Upfront | Zoledronic Acid Delayed Start |
|---|---|---|
| Time to Disease Recurrence/Relapse | NA (NA to NA) | NA (NA to NA) |
The rate of change from baseline in BMD was assessed.
| g/sq cm/month | Zoledronic Acid Upfront | Zoledronic Acid Delayed Start |
|---|---|---|
| Rate of Change From Baseline in Lumbar Spine (L1-L4) BMD | 0.01043 (0.00810 to 0.01277) | -0.00157 (-0.00396 to 0.00081) |
The rate of change from baseline in BMD was assessed.
| g/sq. cm/month | Zoledronic Acid Upfront | Zoledronic Acid Delayed Start |
|---|---|---|
| Rate of Change From Baseline in Total Hip BMD | 0.00226 (0.00071 to 0.00382) | -0.00625 (-0.00784 to -0.00466) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Zoledronic Acid Upfront | — | 83/300 (27.7%) | 283/300 (94.3%) |
| Zoledronic Acid Delayed-start | — | 71/300 (23.7%) | 275/300 (91.7%) |
| Event | Zoledronic Acid Upfront | Zoledronic Acid Delayed-start |
|---|---|---|
| FallInjury, poisoning and procedural complications | 10/300 | 7/300 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 9/300 | 9/300 |
| Atrial fibrillationCardiac disorders | 4/300 | 4/300 |
| Coronary artery diseaseCardiac disorders | 1/300 | 4/300 |
| Coronary artery occlusionCardiac disorders | 0/300 | 4/300 |
| CholecystitisHepatobiliary disorders | 4/300 | 2/300 |
| PneumoniaInfections and infestations | 4/300 | 3/300 |
| Deep vein thrombosisVascular disorders | 3/300 | 4/300 |
| Chest painGeneral disorders | 3/300 | 1/300 |
| AppendicitisInfections and infestations | 1/300 | 3/300 |
| Event | Zoledronic Acid Upfront | Zoledronic Acid Delayed-start |
|---|---|---|
| ArthralgiaMusculoskeletal and connective tissue disorders | 141/300 | 136/300 |
| Hot flushVascular disorders | 122/300 | 118/300 |
| FatigueGeneral disorders | 101/300 | 88/300 |
| MyalgiaMusculoskeletal and connective tissue disorders | 61/300 | 47/300 |
| Back painMusculoskeletal and connective tissue disorders | 44/300 | 52/300 |
| Bone painMusculoskeletal and connective tissue disorders | 48/300 | 24/300 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 45/300 | 40/300 |
| DepressionPsychiatric disorders | 35/300 | 42/300 |
| InsomniaPsychiatric disorders | 41/300 | 29/300 |
| NauseaGastrointestinal disorders | 39/300 | 40/300 |
| Age, Continuous(years) | Zoledronic Acid Upfront | Zoledronic Acid Delayed-start | Total |
|---|---|---|---|
| Mean | 61.4 ± 9.28 | 61.0 ± 8.92 | 61.2 ± 9.1 |
| Sex: Female, Male(Participants) | Zoledronic Acid Upfront | Zoledronic Acid Delayed-start | Total |
|---|---|---|---|
| Female | 301 | 301 | 602 |
| Male | 0 | 0 | 0 |
The record gives a start of Sep 2002, a primary completion of Jan 2009 and a completion of Jan 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2014, 5 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Zoledronic Acid · Letrozole